HC Wainwright & Co. Reiterates Buy on Sagimet Biosciences, Maintains $29 Price Target

Sagimet Biosciences’ AURORA Phase 3 Clinical Trial Of FASN Inhibitor Denifanstat In Moderate To Severe Acne Is On Track To Initiate Enrollment In Q4 2026

All clinical trial sites identified and CRO retainedPatient screening expected to begin in October 2026,with first patient to be enrolled shortly afterFOSTER CITY, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Sagimet

Sagimet Biosciences shares are trading higher after Citizens raised its price target on the stock from $12 to $29.

Citizens Maintains Market Outperform on Sagimet Biosciences, Raises Price Target to $29

Citizens analyst Jonathan Wolleben maintains Sagimet Biosciences (NASDAQ:SGMT) with a Market Outperform and raises the price target from $12 to $29.